Clinical trials: Cancer Related Pain (Breakthrough Pain)
Cancer, Breakthrough Cancer Pain
Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a rapid onset, high intensity and short duration pain episode, which takes place within stable background pain control.
- Trial name
- REBORN (NCT03564548)
- Testing
- PPP001, Morphine sulfate or Hydromorphone or Oxycodone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tetra Bio-Pharma
Cancer Related Pain (Breakthrough Pain)
A Comparative Study of KW-2246
This is a placebo-controlled, double blind, comparative study to evaluate the efficacy and safety of KW-2246 as rescue medication at an optimal dose, which is determined by dose titration in treating breakthrough pain episodes in…
- Trial name
- 2246-004 (NCT01326689)
- Testing
- KW-2246
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Breakthrough Pain
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
Patients treated in Palliative Care Units are potentially fragile patients, especially in our case, which are cancer patients. The management of these patients is usually done from experience, because these patients rarely meet…
- Trial name
- CAVIDIOPAL (NCT02840500)
- Testing
- No intervention
- Where
- 10 sites in Spain
- Volunteers
- 101 people
- Sponsor
- Angelini Farmacéutica
Breakthrough Cancer Pain
Instanyl® Non-Interventional Study
The aim of this study is to describe the use of Instanyl® (Intranasal fentanyl spray) in the treatment of breakthrough pain (BTP) in cancer patients by success of dose titration and distribution of dose strength.
- Trial name
- INIS (NCT01045603)
- Where
- 65 sites in Denmark, France and 5 more
- Volunteers
- 309 people
- Sponsor
- Takeda
Pain
Conversion From Fast Acting Oral Opioids to Abstral®
The purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl (Abstral) for treatment of breakthrough cancer…
- Trial name
- NCT01315886
- Testing
- SL fentanyl
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Orexo AB
Breakthrough Cancer Pain
Treatment of Breakthrough Cancer Pain According to European Guidelines
Pain is a frequent symptom in cancer patients with a negative impact on the quality of life (QoL).Breakthrough cancer pain (BTcP) is defined as "a transient exacerbation of pain, manifesting spontaneously or related to a specific…
- Trial name
- BEG (NCT04468490)
- Where
- Poland
- Volunteers
- 131 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Cancers, Pain
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00589823
- Testing
- Fentanyl citrate, Immediate release morphine sulphate
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Archimedes Development Ltd
Breakthrough Cancer Pain
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase I/IIa, pharmacokinetic, dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough…
- Trial name
- NCT04713189
- Testing
- Inhaled fentanyl aerosol
- Volunteers
- 96 people
- Sponsor
- Lee's Pharmaceutical Limited
Cancer Pain
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00459277
- Testing
- Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Archimedes Development Ltd
Pain, Cancer
A Phase III Clinical Study of KW-2246
This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as rescue medication for breakthrough pain.
- Trial name
- NCT00683995
- Testing
- KW-2246 (fentanyl citrate)
- Where
- 20 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Breakthrough Cancer Pain
Safety of Fentanyl TAIFUN Treatment
A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate hte Safety of Fentanyl TAIFUN Treatment after titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain…
- Trial name
- FINDS (NCT00822614)
- Testing
- Fentanyl TAIFUN, Opioid
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Akela Pharma, Inc.
Cancers, Pain
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00458510
- Testing
- Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
- Volunteers
- 403 people
- Sponsor
- Archimedes Development Ltd
Quality of Life, Breakthrough Cancer Pain
Observational Registry Study of Quality of Life When Treating BTcP With Abstral
This Observational Registry study is designed to collect self-reported Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program-enrolled patient experience with breakthrough…
- Trial name
- RELIEF (NCT01936636)
- Testing
- Fentanyl
- Where
- 36 sites in United States
- Volunteers
- 164 people
- Sponsor
- Galena Biopharma, Inc.
Pain, Cancer
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
This study is designed to determine whether KW-2246 is superior to placebo and not inferior to immediate-release morphine for the relief of breakthrough pain in cancer patients.
- Trial name
- NCT00684632
- Testing
- KW-2246 (fentanyl citrate)
- Where
- 20 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Breakthrough Cancer Pain
Patient Satisfaction and Quality of Life Impact - PecFent®
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of…
- Trial name
- Qualipec (NCT01693328)
- Testing
- PecFent® (fentanyl) nasal spray
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Archimedes Development Ltd
Cancer, Pain
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Primary Objective: To demonstrate the efficacy of intranasal fentanyl in the treatment of breakthrough pain (BTP) in cancer patients.
- Trial name
- NCT00345735
- Testing
- Fentanyl
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nycomed
Pain, Breakthrough Cancer Pain
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
The primary objective of this study is to evaluate the efficacy of SSR411298 200 mg daily compared to placebo as adjunctive treatment for persistent cancer pain based on Numeric Rating Scale (NRS).
- Trial name
- ACT11705 (NCT01439919)
- Testing
- SSR411298
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sanofi
Breakthrough Pain
Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
In cancer patients, pain is one of the most common symptoms. The range of reported prevalence of pain varies from 33% to 64% including different stages of cancer, during or after anticancer treatment.
- Trial name
- CAVIDIOM (NCT03435120)
- Testing
- No intervention
- Where
- 14 sites in Spain
- Volunteers
- 118 people
- Sponsor
- Angelini Farmacéutica
Pain
An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
The purpose of this study is to evaluate the analgesic effectiveness and safety of 37.5mg Tramadol hydrochloride/325mg Acetaminophen in the treatment of breakthrough pain in cancer patients.
- Trial name
- NCT00576173
- Testing
- tramadol hydrochloride; acetaminophen
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc